Synlogic (SYBX) investor relations material

Executive summary

• Discontinued lead clinical trial (Synpheny-3 for PKU) in February 2024 after internal review indicated it was unlikely to meet its primary endpoint; not due to safety concerns.

• Undertook corporate restructuring, reducing workforce to one full-time employee and engaging consultants to support strategic review and operations.

• Entered into a merger agreement with Caldera Therapeutics on July 28, 2026; combined company to focus on Caldera's CLD-423 for IBD and immune-mediated diseases.

• Delisted from Nasdaq in January 2026; shares now quoted on OTCID Basic Market.

Financial highlights

• Net loss of $0.54 million for Q2 2026, compared to $0.53 million net loss in Q2 2025.

• Net income of $0.14 million for the six months ended June 30, 2026, versus a net loss of $0.21 million for the same period in 2025.

• Operating expenses for Q2 2026 were $1.01 million, up from $0.78 million in Q2 2025; six-month operating expenses rose to $2.33 million from $1.68 million year-over-year.

• Cash and cash equivalents totaled $13.2 million as of June 30, 2026, down from $14.7 million at year-end 2025.

Outlook and guidance

• Current cash and cash equivalents expected to fund operations for at least the next 12 months from the filing date.

• Expenses anticipated to remain stable in the near term as the company explores strategic alternatives and merger completion.

• No expectation of product revenue generation; future funding needs depend on strategic transactions and other factors.